Inclusion Criteria:  Hospitalized diabetic adults with laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) in any respiratory specimen within 10 days prior to randomization or *Hospitalized diabetic adults with typical features of COVID-19 for 10 days prior to randomization, not yet tested for SARS-CoV-2 infection by PCR in any respiratory specimen.  RT-PCR for SARS-CoV-2 will be performed within 48 hours of enrollment and excluded from the study if found to be negative. 8-point ordinal scale "category 5" patients, but O2 requirement not more than 10L / min. The subject provides informed consent before initiating any study procedures and understands and agrees to comply with planned study procedures  Exclusion Criteria:  Patients with evidence (clinical, hematological, microbiological or imaging ) of sepsis or any acute/subacute coinfection at the time of enrollment. Patients who have already received any of the study drugs prior to randomization. Patients with severe renal and/or hepatic impairment (eGFR <30 mL/min [EPI-CKD formula] or serum ALT more than 5 times normal upper limit, serum bilirubin > 2 mg/dl). Patients with known COPD. Patients with absolute neutrophil count <700 cells/microliter, 0.7 x 103/microliter. Patients with absolute lymphocyte count <200 cells/microliter, 0.20 x 103/microliter. Patients who are allergic to any of the study drugs. Patients with chronic infections, such as tuberculosis (TB), HIV infection etc. Immunosuppressed patients, such as taking cytotoxic/immunomodulating drugs or systemic steroid.